11111111111111111111111111#11j1)R11]11011121,1111111111111111111111111
`11111111111111111111111111#11j1)R11]11011121,1111111111111111111111111
`
`IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
`US008685930B2
`
`(12) United States Patent (cid:9)
`(12) United States Patent (cid:9)
`lI2j United States Patent
`Acheampong et al. (cid:9)
`Acheampong et al. (cid:9)
`et al.
`Acheampong
`
`(Io) Patent No. :
`(10) Patent No.: (cid:9)
`(10) Patent No.: (cid:9)
`(45) Date of Patent:
`(45) Date of Patent: (cid:9)
`(45) Date of Patent: (cid:9)
`
`US 8,685,930 B2
`US 8,685,930 B2
`US 8,685,930 B2
`*Apr. 1, 2014
`*Apr. 1, 2014
`*Apr. 1, 2014
`
`(54) METHODS OF PROVIDING THERAPEUTIC
`(54) METHODS OF PROVIDING THERAPEUTIC
`(54) METHODS OF PROVIDING THERAPEUTIC
`EFFECTS USING CYCLOSPORIN
`EFFECTS USING CYCLOSPORIN
`EFFECTS USING CYCLOSPORIN
`COMPONENTS
`COMPONENTS
`COMPONENTS
`
`Inc., Irvine, CA (US)
`(71) Applicant: Allergan, Inc., Irvine, CA (US)
`(71) Applicant: Allergan, Inc., Irvine, CA (US)
`(71) Applicant: Allergan,
`
`(72)
`(72)
`(72)
`
`Inventors: Andrew Acheampong, Irvine, CA (US);
`Inventors: Andrew Acheampong, Irvine, CA (US);
`Irvine, CA(US);
`Inventors: AndrewAcheampong,
`Diane D. Tang-Liu, Las Vegas, NV
`Diane D. Tang-Liu, Las Vegas, NV
`Diane D. Tang-Liu, Las Vegas, NV
`(US); James N. Chang, Newport Beach,
`(US); James N. Chang, Newport Beach,
`(US); James N. Chang, Newport Beach,
`CA (US); David F. Power, Hubert, NC
`CA (US); David F. Power, Hubert, NC
`CA (US); David F. Power, Hubert, NC
`(US)
`(US)
`(US)
`
`Inc., Irvine, CA (US)
`(73) Assignee: Allergan, Inc., Irvine, CA (US)
`(73) Assignee: Allergan, Inc., Irvine, CA (US)
`(73) Assignee: Allergan,
`( * ) Notice:
`Notice: (cid:9)
`Notice: (cid:9)
`* )
`* )
`
`the term of this
`Subject to any disclaimer, the term of this
`Subject to any disclaimer, the term of this
`Subject to any disclaimer,
`patent is extended or adjusted under 35
`patent is extended or adjusted under 35
`is extended or adjusted under 35
`patent
`U.S.C. 154(b) by 0 days.
`U.S.C. 154(b) by 0 days.
`U.S.C. 154(b) by 0 days.
`This patent is subject to a terminal dis-
`This patent is subject to a terminal dis-
`dis-
`to a terminal
`is subject
`This patent
`claimer.
`claimer.
`claimer.
`
`(21) Appl. No.: 13/961,828
`(21) Appl. No.: 13/961,828
`(21) Appl. Noz 13/961,S2S
`
`(22) Filed: (cid:9)
`(22) Filed: (cid:9)
`Filed:
`(22)
`
`Aug. 7, 2013
`Aug. 7, 2013
`Aug. 7, 2013
`
`(65) (cid:9)
`(65) (cid:9)
`(65)
`
`Prior Publication Data
`Prior Publication Data
`Prior Publication Data
`Dec. 19, 2013
`US 2013/0338082 Al
`US 2013/0338082 Al (cid:9)
`Dec. 19, 2013
`US 2013/0338082 Al (cid:9)
`Dec. 19, 2013
`
`Related U.S.Application Data
`Related U.S. Application Data
`Related U.S. Application Data
`(63) Continuation of application No. 11/897, 177, filed on
`(63) Continuation of application No. 11/897,177, filed on
`(63) Continuation of application No. 11/897,177, filed on
`Aug. 28, 2007, now Pat. No. 8,618,064, and a
`Aug. 28, 2007, now Pat. No. 8,618,064, and a
`Aug. 28, 2007, now Pat. No. 8,618,064, and a
`continuation of application No. 10/927, 857, filed on
`continuation of application No. 10/927,857, filed on
`continuation of application No. 10/927,857, filed on
`Aug. 27, 2004, now abandoned.
`Aug. 27, 2004, now abandoned.
`Aug. 27, 2004, now abandoned.
`(60) Provisional application No. 60/503,137, filed on Sep.
`(60) Provisional application No. 60/503,137, filed on Sep.
`application No. 60/503, 137, filed on Sep.
`(60)
`Provisional
`15, 2003.
`15, 2003.
`15, 2003.
`
`(2006.01)
`(2006.01)
`(2006.01)
`
`Int. Cl.
`(51) Int. Cl.
`(51) Int. Cl.
`(51)
`zl 61K38/13
`A61K 38/13 (cid:9)
`A61K 38/13 (cid:9)
`(52) U.S. Cl.
`(52) U.S. Cl.
`(52) U.S. Cl.
`USPC (cid:9)
`USPC (cid:9)
`USPC
`(58) Field of ClassiTication Search
`(58) Field of Classification Search
`(58) Field of Classification Search
`A61K 38/13
` A61K 38/13
`CPC (cid:9)
` A61K 38/13
`CPC (cid:9)
`CPC .........................................
`See application file for complete search history.
`See application file for complete search history.
`See application file for complete search history.
`
` 514/20.5
` 514/20.5
`514/20. 5
`
`(56)
`(56)
`(56)
`
`References Cited
`References Cited
`References Cited
`
`5,342,625
`5,342,625
`5,342,625 A
`5,368,854
`5,368,854
`5,368,854 A
`5,411,952 A
`5,411,952
`5,411,952
`5,424,078
`5,424,078
`5,424, 078 A
`5,474,919 A
`5,474,919
`5,474,919
`5,474,979 A
`5,474,979
`5,474,979
`5,504,068
`5,504,068
`5,504,068 A
`5,540,931 A
`5,540,931
`5,540,931
`5,543,393 A
`5,543,393
`5,543,393
`5,589,455
`5,589,455
`5,589,455 A
`5,591,971 A
`5,591,971
`5,591,971
`5,614,491 A
`5,614,491
`5,614,491
`5,639,724
`5,639,724
`5,639,724 A
`5,652,212 A
`5,652,212
`5,652,212
`5,719,123 A
`5,719,123
`5,719,123
`5,739,105
`5,739,105
`5,739,105 A
`5,753,166
`5,753,166
`5,753, 166 A
`5,766,629
`5,766,629
`5,766,629 A
`5,798,333 A
`5,798,333
`5,798,333
`5,807,820
`5,807,820
`5,807,820 A
`5,827,822
`5,827,822
`5,827,822 A
`5,827,862
`5,827,862
`5,827,862 A
`5,834,017 A
`5,834,017
`5,834,017
`5,843,452
`5,843,452
`5,843,452 A
`5,843,891
`5,843,891
`5,843,891 A
`5,858,401 A
`5,858,401
`5,858,401
`5,866,159
`5,866,159
`5,866, 159 A
`5,891,846 A
`5,891,846
`5,891,846
`
`8/1994
`Hauer et al.
`8/1994
`Hauer et al.
`8/1994
`Hauer et al.
`11/1994
`Rennick
`11/1994
`Rennick
`11/1994
`Rennick
`5/1995
`Kaswan
`5/1995
`Kaswan
`5/1995
`Kaswan
`6/1995
`Dziabo
`6/1995
`Dziabo
`6/1995
`Dziabo
`12/1995
`Chartrain et al.
`12/1995
`Chartrain et al.
`12/1995
`Chartrain et al.
`12/1995
`Ding et al.
`12/1995
`Ding et al.
`12/1995
`Ding et al.
`4/1996
`Komiya et al.
`4/1996
`Komiya et al.
`4/1996
`Komiya et al.
`7/1996
`Hewitt et al.
`7/1996
`Hewitt et al.
`7/1996
`Hewitt et al.
`8/1996
`Kim et al.
`8/1996
`Kim et al.
`8/1996
`Kim et al.
`12/1996
`Woo
`12/1996
`Woo
`12/1996
`Woo
`I/1997
`1/1997
`Shahar et al.
`1/1997
`Shahar et al.
`Shahar et al.
`3/1997
`Walch et al.
`3/1997
`Walch et al.
`3/1997
`Walch et al.
`6/1997
`Cavanak
`6/1997
`Cavanak
`6/1997
`Cavanak
`7/1997
`Cavanak et al.
`7/1997
`Cavanak et al.
`7/1997
`Cavanak et al.
`2/1998
`Morley et al.
`2/1998
`Morley et al.
`2/1998
`Morley et al.
`4/1998
`Kim et al.
`4/1998
`Kim et al.
`4/1998
`Kim et al.
`5/1998
`Dalton et al.
`5/1998
`Dalton et al.
`5/1998
`Dalton et al.
`6/1998
`Cho et al.
`6/1998
`Cho et al.
`6/1998
`Cho et al.
`8/1998
`Sherman
`8/1998
`Sherman
`8/1998
`Sherman
`9/1998
`Elias
`9/1998
`Elias
`9/1998
`Elias
`Floch'h et al.
`10/1998
`Floch'h et al.
`10/1998
`Floch'h et al.
`10/1998
`10/1998
`Yamamura
`10/1998
`Yamamura
`10/1998
`Yamamura
`11/1998
`Cho et al.
`11/1998
`Cho et al.
`11/1998
`Cho et al.
`12/1998
`Wiedmann et al.
`12/1998
`Wiedmann et al.
`12/1998
`et al.
`Wiedmann
`12/1998
`Sherman
`12/1998
`Sherman
`12/1998
`Sherman
`I/1999
`1/1999
`Bhalani et al.
`1/1999
`Bhalani et al.
`Bhalani et al.
`2/1999
`Hauer et al.
`2/1999
`Hauer et al.
`2/1999
`Hauer et al.
`4/1999
`Ishida et al.
`4/1999
`Ishida et al.
`4/1999
`Ishida et al.
`(Continued)
`(Continued)
`(Continued)
`
`FOREIGN PATENT DOCUMENTS
`FOREIGN PATENT DOCUMENTS
`FOREIGN PATENT DOCUMENTS
`
`DE
`DE
`DE
`EP
`EP
`EP
`
`19810655
`9/1999
`9/1999
`19810655 (cid:9)
`9/1999
`19810655 (cid:9)
`0471293
`2/1992
`0471293 (cid:9)
`2/1992
`0471293 (cid:9)
`2/1992
`(Continued)
`(Continued)
`(Continued)
`
`OTHER PUBLICATIONS
`OTHER PUBLICATIONS
`OTHER PUBLICATIONS
`
`U.S. Appl. No. 90/009, 944 and its entire prosecution history,
`U.S. Appl. No. 90/009,944 and its entire prosecution history, filed
`U.S. Appl. No. 90/009,944 and its entire prosecution history, filed
`filed
`AUQ. 27, 2011.
`Aug. 27, 2011.
`Aug. 27, 2011.
`Abdulrazik, M, et al, Ocular Delivery of Cyclosporin A H, Effect of
`Abdulrazik, M. et al, Ocular Delivery of Cyclosporin A II. Effect of
`Abdulrazik, M. et al, Ocular Delivery of Cyclosporin A II. Effect of
`Surface Charge on Ocular Distribution of
`Submicron Emulsion's Surface Charge on Ocular Distribution of
`Submicron Emulsion's Surface Charge on Ocular Distribution of
`Submicron Emulsion's
`Topical Cyclosporin A, S.T.P. Pharma Sciences, Dec. 2001, 427-432,
`Topical Cyclosporin A, S.T.P. Pharma Sciences, Dec. 2001, 427-432,
`Topical Cyclosporin A, S.T.P. Pharma Sciences, Dec. 2001, 427-432,
`11(6).
`11(6).
`I tl61.
`Acheampong, Andrew et al, Cyclosporine Distribution into The Con-
`Acheampong, Andrew et al, Cyclosporine Distribution into The Con-
`Acheampong, Andrew et al, Cyclosporine Distribution into The Con-
`junctiva, Cornea, Lacrimal Gland and Systemic Blood Following
`junctiva, Cornea, Lacrimal Gland and Systemic Blood Following
`junctiva, Cornea, Lacrimal Gland and Systemic Blood Following
`Topical Dosing of Cyclosporine
`Topical Dosing of Cyclosporine to Rabbit, Dog and Human eyes,
`Topical Dosing of Cyclosporine to Rabbit, Dog and Human eyes,
`to Rabbit, Dog and Human
`eyes,
`1996, 179.
`1996, 179.
`1996, 179.
`Acheampong, Andrew et al, Cyclosporine Distribution Into the Con-
`Acheampong, Andrew et al, Cyclosporine Distribution Into the Con-
`Acheampong, Andrew et al, Cyclosporine Distribution Into the Con-
`junctiva, Cornea, Lacrimal Gland, and Systemic Blood Following
`junctiva, Cornea, Lacrimal Gland, and Systemic Blood Following
`junctiva, Cornea, Lacrimal Gland, and Systemic Blood Following
`Topical Dosing of Cyclosporine
`Topical Dosing of Cyclosporine to Rabbit, Dog, and Human Eyes,
`Topical Dosing of Cyclosporine to Rabbit, Dog, and Human Eyes,
`to Rabbit, Dog, and Human Eyes,
`Adv. Exp. Med. Biol., 1998, 1001-1004, 438.
`Adv. Exp. Med. Biol., 1998, 1001-1004, 438.
`Adv. Exp. Med. Biol., 1998, 1001-1004, 438.
`
`U.S. PATENT DOCUMENTS
`U.S. PATENT DOCUMENTS
`U.S. PATENT DOCUMENTS
`
`(Continued)
`(Continued)
`(Continued)
`
`3,278,447 A (cid:9)
`3,278,447 A (cid:9)
`3,278,447 A
`4,388,229 A (cid:9)
`4,388,229 A (cid:9)
`4,388,229 A
`4,388,307 A
`4,388,307 A (cid:9)
`4,388,307 A (cid:9)
`4,614,736 A
`4,614,736 A (cid:9)
`4,614,736 A (cid:9)
`4,649,047 A (cid:9)
`4,649,047 A (cid:9)
`4,649,047 A
`4,764,503 A (cid:9)
`4,764,503 A (cid:9)
`4,764,503 A
`4,814,323 A (cid:9)
`4,814,323 A (cid:9)
`4,814,323 A
`4,839,342 A (cid:9)
`4,839,342 A (cid:9)
`4,839,342 A
`4,970,076 A (cid:9)
`4,970,076 A (cid:9)
`4,970,076 A
`4,990,337 A
`4,990,337 A (cid:9)
`4,990,337 A (cid:9)
`4,996,193 A (cid:9)
`4,996,193 A (cid:9)
`4,996,193 A
`5,047,396 A
`5,047,396 A (cid:9)
`5,047,396 A (cid:9)
`5,051,402 A
`5,051,402 A (cid:9)
`5,051,402 A (cid:9)
`5,053,000 A (cid:9)
`5,053,000 A (cid:9)
`5,053,000 A
`5,286,730 A
`5,286,730 A (cid:9)
`5,286,730 A (cid:9)
`5,286,731 A
`5,286,731 A (cid:9)
`5,286,731 A (cid:9)
`5,294,604 A (cid:9)
`5,294,604 A (cid:9)
`5,294,604 A
`5,296,158 A (cid:9)
`5,296,158 A (cid:9)
`5,296, 158 A
`
`10/1966 McNicholas
`10/1966 McNicholas
`10/1966
`McNicholas
`6/1983 Fu
`6/1983 Fu
`6/1983
`Fu
`6/1983 Cavanak
`6/1983 Cavanak
`6/1983
`Cavanak
`9/1986 Delevallee et al.
`9/1986 Delevallee et al.
`9/1986
`Delevallee et al.
`3/1987 Kaswan
`3/1987 Kaswan
`3/1987
`Kaswan
`8/1988 Wenger
`8/1988 Wenger
`8/19gg
`Wenger
`3/1989 Andrieu et al.
`3/1989 Andrieu et al.
`3/1989
`Andrieu et al.
`6/1989 Kaswan
`6/1989 Kaswan
`6/1989
`Kaswan
`11/1990
`11/1990 Horrobin
`11/1990 Horrobin
`Horrobin
`2/1991 Kurihara et al.
`2/1991 Kurihara et al.
`2/1991
`Kurihara et al.
`2/1991 Hewitt et al.
`2/1991 Hewitt et al.
`2/1991
`Hewitt et al.
`9/1991 Orban et al.
`9/1991 Orban et al.
`9/1991
`Orban et al.
`9/1991 Kurihara et al.
`9/1991 Kurihara et al.
`9/1991
`Kurihara et al.
`10/1991 Booth et al.
`10/1991 Booth et al.
`10/1991
`Booth et al.
`2/1994 Caufield et al.
`2/1994 Caufield et al.
`2/1994
`Caufield et al.
`2/1994 Caufield et al.
`2/1994 Caufield et al.
`2/1994
`Caufield et al.
`3/1994 Nussenblatt et al.
`3/1994 Nussenblatt et al.
`3/1994
`et al.
`Nussenblatt
`3/1994 MacGilp et al.
`3/1994 MacGilp et al.
`3/1994
`MacGilp et al.
`
`Primary Examiner — Marcela M Cordero Garcia
`Primary Examiner — Marcela M Cordero Garcia
`Primary Examiner
`Marcela M Cordero Garcia
`Joel B.
`Laura L. Wine;
`(74) Attorney, Agent, or Firm
`(74) Attorney, Agent, or Firm Laura L. Wine; Joel B.
`(74) Attorney, Agent, or Firm Laura L. Wine; Joel B.
`German; Debra D. Condino
`German; Debra D. Condino
`German; Debra D. Condino
`
`ABSTRACT
`ABSTRACT
`ABSTRACT
`(57) (cid:9)
`(57) (cid:9)
`(57)
`Methods of treating an eye of a human or animal
`Methods of treating an eye of a human or animal include
`Methods of treating an eye of a human or animal include
`include
`to an eye of a human or animal a composition
`administering to an eye of a human or animal a composition
`administering to an eye of a human or animal a composition
`administering
`in the form of an emulsion including water, a hydrophobic
`in the form of an emulsion including water, a hydrophobic
`in the form of an emulsion including water, a hydrophobic
`component and a cyclosporin component in a therapeutically
`component and a cyclosporin component in a therapeutically
`in a therapeutically
`and a cyclosporin component
`component
`effective amount of less than 0.1'zo by weight of the compo-
`effective amount of less than 0.1% by weight of the compo-
`effective amount of less than 0.1% by weight of the compo-
`ratio of the cyclosporin component
`sition. The weight ratio of the cyclosporin component to the
`sition. The weight ratio of the cyclosporin component to the
`sition. The weight
`to the
`is less than 0.8.
`hydrophobic component is less than 0.8.
`hydrophobic component is less than 0.8.
`component
`hydrophobic
`
`36 Claims, No Drawings
`36 Claims, No Drawings
`36 Claims, No Drawings
`
`TEVA - EXHIBIT 1001
`
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`

`
`US 8,685,930 B2
`US 8,685,930 B2
`US 8,685,930 B2
`Page 2
`Page 2
`Page 2
`
`2005/0014691 Al
`2005/0014691 Al (cid:9)
`2005/0014691 Al (cid:9)
`2005/0059583 Al
`2005/0059583 Al (cid:9)
`2005/0059583 Al (cid:9)
`2007/0015691 Al
`2007/0015691 Al (cid:9)
`2007/0015691 Al (cid:9)
`2007/0027072 Al
`2007/0027072 Al (cid:9)
`2007/0027072 Al (cid:9)
`2007/0087962 Al
`2007/0087962 Al (cid:9)
`2007/0087962 Al (cid:9)
`2007/0149447 Al
`2007/0149447 Al (cid:9)
`2007/0149447 Al (cid:9)
`2007/0299004 Al
`2007/0299004 Al (cid:9)
`2007/0299004 Al (cid:9)
`2008/0039378 Al
`2008/0039378 Al (cid:9)
`2008/0039378 Al (cid:9)
`2008/0070834 Al
`2008/0070834 Al (cid:9)
`2008/0070834 Al (cid:9)
`2008/0146497 Al
`2008/0146497 Al (cid:9)
`2008/0146497 Al (cid:9)
`2008/0207495 Al
`2008/0207495 Al (cid:9)
`2008/0207495 Al (cid:9)
`2009/0131307 Al
`2009/0131307 Al (cid:9)
`2009/0131307 Al (cid:9)
`2010/0279951 Al
`2010/0279951 Al (cid:9)
`2010/0279951 Al (cid:9)
`2011/0009339 Al
`2011/0009339 Al (cid:9)
`2011/0009339 Al (cid:9)
`2011/0294744 Al
`2011/0294744 Al (cid:9)
`2011/0294744 Al (cid:9)
`2012/0270805 Al
`2012/0270805 Al (cid:9)
`2012/0270805 Al (cid:9)
`2013/0059796 Al
`2013/0059796 Al (cid:9)
`2013/0059796 Al (cid:9)
`
`1/2005 (cid:9) Bakhit et al.
`1/2005 (cid:9) Bakhit et al.
`I/2005
`Bakhit et al.
`3/2005 (cid:9) Acheampong
`3/2005 (cid:9) Acheampong
`3/2005
`Acheampong
`1/2007 (cid:9) Chang
`1/2007 (cid:9) Chang
`I/2007
`Chang
`2/2007 (cid:9) Tien et al.
`2/2007 (cid:9) Tien et al.
`Tien et al.
`2/2007
`4/2007 (cid:9) Tien et al.
`4/2007 (cid:9) Tien et al.
`Tien et al.
`4/2007
`6/2007 (cid:9) Chang et al.
`6/2007 (cid:9) Chang et al.
`Chang et al.
`6/2007
`12/2007 (cid:9) Acheampong et al.
`12/2007 (cid:9) Acheampong et al.
`et al.
`12/2007
`Acheampong
`2/2008 (cid:9) Graham et al.
`2/2008 (cid:9) Graham et al.
`Graham et al.
`2/2008
`3/2008 (cid:9) Chang et al.
`3/2008 (cid:9) Chang et al.
`Chang et al.
`3/2008
`6/2008 (cid:9) Graham et al.
`6/2008 (cid:9) Graham et al.
`Graham et al.
`6/2008
`8/2008 (cid:9) Graham et al.
`8/2008 (cid:9) Graham et al.
`Graham et al.
`g/2008
`5/2009 (cid:9) Tien et al.
`5/2009 (cid:9) Tien et al.
`Tien et al.
`5/2009
`11/2010 (cid:9) Morgan et al.
`11/2010 (cid:9) Morgan et al.
`11/2010
`Morgan et al.
`1/2011 (cid:9) Schiffman
`1/2011 (cid:9) Schiffman
`I/2011
`Schiffman
`12/2011 (cid:9) Morgan et al.
`12/2011 (cid:9) Morgan et al.
`12/2011
`Morgan et al.
`10/2012 (cid:9) Chang et al.
`10/2012 (cid:9) Chang et al.
`10/2012
`Chang et al.
`3/2013 (cid:9) Chang et al.
`3/2013 (cid:9) Chang et al.
`3/2013
`Chang et al.
`
`FOREIGN PATENT DOCUMENTS
`FOREIGN PATENT DOCUMENTS
`FOREIGN PATENT DOCUMENTS
`
`EP (cid:9)
`EP (cid:9)
`EP
`EP (cid:9)
`EP (cid:9)
`EP
`WO (cid:9)
`WO (cid:9)
`WO
`WO (cid:9)
`WO (cid:9)
`WO
`WO (cid:9)
`WO (cid:9)
`WO
`WO (cid:9)
`WO (cid:9)
`WO
`WO (cid:9)
`WO (cid:9)
`WO
`WO (cid:9)
`WO (cid:9)
`WO
`WO (cid:9)
`WO (cid:9)
`WO
`WO (cid:9)
`WO (cid:9)
`WO
`
`0547229 (cid:9)
`0547229 (cid:9)
`0547229
`0760237
`0760237 (cid:9)
`0760237 (cid:9)
`95-31211
`95-31211 (cid:9)
`95-31211 (cid:9)
`00-00179
`00-00179 (cid:9)
`00-00179 (cid:9)
`01-32142
`01-32142 (cid:9)
`01-32142 (cid:9)
`01-41671
`01-41671 (cid:9)
`01-41671 (cid:9)
`02-09667
`02-09667 (cid:9)
`02-09667 (cid:9)
`02-49603
`02-49603 (cid:9)
`02-49603 (cid:9)
`03-030834
`03-030834 (cid:9)
`03-030834 (cid:9)
`03-053405
`03-053405 (cid:9)
`03-053405 (cid:9)
`
`I/1993
`1/1993
`1/1993
`3/1997
`3/1997
`3/1997
`11/1995
`11/1995
`11/1995
`1/2000
`1/2000
`I/2000
`5/2001
`5/2001
`5/2001
`6/2001
`6/2001
`6/2001
`2/2002
`2/2002
`2/2002
`6/2002
`6/2002
`6/2002
`4/2003
`4/2003
`4/2003
`7/2003
`7/2003
`7/2003
`
`OTHER PUBLICATIONS
`OTHER PUBLICATIONS
`OTHER PUBLICATIONS
`Acheampong, Andrew et al, Distribution of Cyclosporin A in Ocular
`Acheampong, Andrew et al, Distribution of Cyclosporin A in Ocular
`Acheampong, Andrew et al, Distribution of Cyclosporin A in Ocular
`Tissues After Topical Administration to Albino Rabbits and Beagle
`Tissues After Topical Administration to Albino Rabbits and Beagle
`to Albino Rabbits and Beagle
`Tissues After Topical Administration
`Dogs, Current Eye Research, 1999, 91-103, I gi2i.
`Dogs, Current Eye Research, 1999, 91-103, 18(2).
`Dogs, Current Eye Research, 1999, 91-103, 18(2).
`Trial of Topical
`Akpek, Esen Karamursel et al, A Randomized Trial of Topical
`Akpek, Esen Karamursel et al, A Randomized Trial of Topical
`Akpek, Esen Karamursel
`et al, A Randomized
`0,05% in
`Cyclosporin (cid:9)
`0.05% (cid:9)
`in (cid:9)
`Topical (cid:9)
`Steroid-Resistant (cid:9) Atopic
`Cyclosporin (cid:9)
`0.05% (cid:9)
`in (cid:9)
`Topical (cid:9)
`Steroid-Resistant (cid:9) Atopic
`Steroid-Resistant
`Atopic
`Cyclosporin
`Topical
`2004, 476-482, 111.
`Keratoconjunctivitis, Ophthalmology, 2004, 476-482, 111.
`Keratoconjunctivitis, Ophthalmology, 2004, 476-482, 111.
`Keratoconjunctivitis, Ophthalmology,
`Angelov, 0, et al, Preclinical
`Safety Studies of Cyclosporine
`Angelov, 0. et al, Preclinical Safety Studies of Cyclosporine
`Angelov, 0. et al, Preclinical Safety Studies of Cyclosporine
`Ophthalmic Emulsion, Adv Exp Med Biol, 1998, 991-995, 438.
`Ophthalmic Emulsion, Adv Exp Med Biol, 1998, 991-995, 438.
`Ophthalmic Emulsion, Adv Exp Med Biol, 1998, 991-995, 438.
`Angelov, 0, et al, Safety Assessment of Cyclosporine Ophthalmic
`Angelov, 0. et al, Safety Assessment of Cyclosporine Ophthalmic
`Angelov, 0. et al, Safety Assessment of Cyclosporine Ophthalmic
`Emulsion in Rabbits and Dogs, XIth Congress of the European Soci-
`Emulsion in Rabbits and Dogs, XIth Congress of the European Soci-
`Emulsion in Rabbits and Dogs, XIth Congress of the European Soci-
`ety of Ophthalmology,
`1997, 25-28, 1-5, Soc. Ophthalmol Eur. , HU.
`ety of Ophthalmology, 1997, 25-28, 1-5, Soc. Ophthalmol Eur., HU.
`ety of Ophthalmology, 1997, 25-28, 1-5, Soc. Ophthalmol Eur., HU.
`Ardizzone, Sandro et al, A Practical Guide to the Management of
`Ardizzone, Sandro et al, A Practical Guide to the Management of
`Ardizzone, Sandro et al, A Practical Guide to the Management of
`Distal Ulcerative Colitis, Drugs, 1998, 519-542, 55i4i.
`Distal Ulcerative Colitis, Drugs, 1998, 519-542, 55(4).
`Distal Ulcerative Colitis, Drugs, 1998, 519-542, 55(4).
`in a Murine Model of
`Banic, Marko et al, Effect of Cyclosporine
`Banic, Marko et al, Effect of Cyclosporine in a Murine Model of
`Banic, Marko et al, Effect of Cyclosporine in a Murine Model of
`Experimental Colitis, Digestive Diseases and Sciences, Jun. 2002,
`Experimental Colitis, Digestive Diseases and Sciences, Jun. 2002,
`Experimental Colitis, Digestive Diseases and Sciences, Jun. 2002,
`1362-1368, 47i6i.
`1362-1368, 47(6).
`1362-1368, 47(6).
`Bonini, S, et al, Vernal Keratoconjunctivitis, Eye, 2004, 345-351, 18.
`Bonini, S. et al, Vernal Keratoconjunctivitis, Eye, 2004, 345-351, 18.
`Bonini, S. et al, Vernal Keratoconjunctivitis, Eye, 2004, 345-351, 18.
`Brewster, Marcus et al, Enhanced Delivery of Ganciclovir
`Brewster, Marcus et al, Enhanced Delivery of Ganciclovir to the
`Brewster, Marcus et al, Enhanced Delivery of Ganciclovir to the
`to the
`Brain Through the Use of Redox Targeting, Antimicrobial Agents
`Brain Through the Use of Redox Targeting, Antimicrobial Agents
`Brain Through the Use of Redox Targeting, Antimicrobial Agents
`and Chemotherapy, Apr. 1994, 817-823, 38i4i.
`and Chemotherapy, Apr. 1994, 817-823, 38(4).
`and Chemotherapy, Apr. 1994, 817-823, 38(4).
`Brewster, Marcus et al, Intravenous and Oral Pharmacokinetic Evalu-
`Brewster, Marcus et al, Intravenous and Oral Pharmacokinetic Evalu-
`and Oral Pharmacokinetic Evalu-
`Brewster, Marcus et al, Intravenous
`Formulation of
`ation of a 2-Hydroxypropyl-i3-cyclodextrin-Based
`ation of a 2-Hydroxypropy1-13-cyclodextrin-Based Formulation of
`ation of a 2-Hydroxypropy1-13-cyclodextrin-Based Formulation of
`Carbamazepine in the Dog: Comparison with Commercially Avail-
`Carbamazepine in the Dog: Comparison with Commercially Avail-
`in the Dog; Comparison with Commercially Avail-
`Carbamazepine
`Journal of Pharmaceutical
`able Tablets and Suspensions, Journal of Pharmaceutical Sciences,
`able Tablets and Suspensions, Journal of Pharmaceutical Sciences,
`Sciences,
`able Tablets and Suspensions,
`MaL 1997, 335-339, 86i3i.
`Mar. 1997, 335-339, 86(3).
`Mar. 1997, 335-339, 86(3).
`Brewster, Marcus et al, Preparation, Characterization, and Anesthetic
`Brewster, Marcus et al, Preparation, Characterization, and Anesthetic
`Brewster, Marcus et al, Preparation, Characterization,
`andAnesthetic
`of 2-Hydroxypropyl-i3-cyclodextrin
`of
`Properties (cid:9) of (cid:9) 2-Hydroxypropy1-13-cyclodextrin (cid:9) Complexes (cid:9) of
`Properties (cid:9) of (cid:9) 2-Hydroxypropy1-13-cyclodextrin (cid:9) Complexes (cid:9) of
`Complexes
`Properties
`in Rat and Mouse, Journal of Phar-
`Pregnanolone and Pregnenolone in Rat and Mouse, Journal of Phar-
`Pregnanolone and Pregnenolone in Rat and Mouse, Journal of Phar-
`Pregnanolone
`and Pregnenolone
`maceutical Sciences, Oct. 1995, 1154-1159,84iIOi.
`maceutical Sciences, Oct. 1995, 1154-1159, 84(10).
`maceutical Sciences, Oct. 1995, 1154-1159, 84(10).
`Brinkmeier, Thomas et al, Pyodermatitis-Pyostomatitis Vegetans: A
`Brinkmeier, Thomas et al, Pyodermatitis-Pyostomatitis Vegetans: A
`Brinkmeier, Thomas et al, Pyodermatitis-Pyostomatitis
`Vegetans: A
`Clinical Course of Two Decades with Response to Cyclosporine
`Clinical Course of Two Decades with Response to Cyclosporine and
`Clinical Course of Two Decades with Response to Cyclosporine and
`and
`Low-Dose Prednisolone, Acta Derm Venereol, 2001, 134-136, 81.
`Low-Dose Prednisolone, Acta Derm Venereol, 2001, 134-136, 81.
`Low-Dose Prednisolone, Acta Derm Venereol, 2001, 134-136, 81.
`Castillo, Jose M. Benitez Del et al, Influence ofTopical Cyclosporine
`Castillo, Jose M. Benitez Del et al, Influence of Topical Cyclosporine
`Castillo, Jose M. Benitez Del et al, Influence of Topical Cyclosporine
`A and Dissolvent on Corneal Epithelium Permeability of Fluores-
`A and Dissolvent on Corneal Epithelium Permeability of Fluores-
`A and Dissolvent on Corneal Epithelium Permeability of Fluores-
`1995, 49-55, 91.
`cein, Documenta Ophthalmologica, 1995, 49-55, 91.
`cein, Documenta Ophthalmologica, 1995, 49-55, 91.
`cein, Documenta Ophthalmologica,
`Cheeks, Lisa et al, Influence ofVehicle and Anterior Chamber Protein
`Cheeks, Lisa et al, Influence ofVehicle and Anterior Chamber Protein
`Cheeks, Lisa et al, Influence ofVehicle and Anterior Chamber Protein
`Concentration on Cyclosporine Penetration Through the Isolated
`Concentration on Cyclosporine Penetration Through the Isolated
`the Isolated
`Concentration
`on Cyclosporine
`Penetration Through
`Rabbit Cornea, Current Eye Research, 1992, 641-649, I Ii7i.
`Rabbit Cornea, Current Eye Research, 1992, 641-649, 11(7).
`Rabbit Cornea, Current Eye Research, 1992, 641-649, 11(7).
`Database WPI Week 200044, Derwent Pub. Ltd., London, GB; An
`Database WPI Week 200044, Derwent Pub. Ltd., London, GB; An
`Database WPI Week 200044, Derwent Pub. Ltd. , London, GB; An
`2000-492678 & JP2000/143542, 2000, 2 Pages.
`2000-492678 & JP2000/143542, 2000, 2 Pages.
`2000-492678 & JP2000/143542, 2000, 2 Pages.
`Ding, Shulin et al, Cyclosporine Ophthalmic 0/W emulsion: Formu-
`Ding, Shulin et al, Cyclosporine Ophthalmic 0/W emulsion: Formu-
`Ding, Shulin et al, Cyclosporine Ophthalmic 0/W emulsion: Formu-
`lation and Emulsion Characterization, Pharm Res, 1997, 1 page, 14
`lation and Emulsion Characterization, Pharm Res, 1997, 1 page, 14
`Pharm Res, 1997, I page, 14
`lation and Emulsion Characterization,
`i I ii.
`(11).
`(11).
`Donnenfeld, Eric D., The Economics ofUsing Restasis, Ophthalmol-
`Donnenfeld, Eric D., The Economics of Using Restasis, Ophthalmol-
`Donnenfeld, Eric D., The Economics of Using Restasis, Ophthalmol-
`ogy Management, Oct. 2003, 3 pages, US.
`ogy Management, Oct. 2003, 3 pages, US.
`ogy Management, Oct. 2003, 3 pages, US.
`
` 514/20.8
` 514/20.8
`514/20. 8
`
`(56)
`(56) (cid:9)
`(56) (cid:9)
`
`References Cited
`References Cited
`References Cited
`
`U.S. PATENT DOCUMENTS
`U.S. PATENT DOCUMENTS
`U.S. PATENT DOCUMENTS
`
`6/1999 Hauer et al.
`6/1999 Hauer et al.
`6/1999
`Hauer et al.
`7/1999 Hamied et al.
`7/1999 Hamied et al.
`7/1999
`Hamied et al.
`9/1999 Kawashima et al.
`9/1999 Kawashima et al.
`9/1999
`et al.
`Kawashima
`10/1999 Hauer et al.
`10/1999 Hauer et al.
`10/1999
`Hauer et al.
`10/1999 Hauer et al.
`10/1999 Hauer et al.
`10/1999
`Hauer et al.
`10/1999 Cho et al.
`10/1999 Cho et al.
`10/1999
`Cho et al.
`11/1999
`11/1999 Cavanak
`11/1999 Cavanak
`Cavanak
`11/1999
`11/1999 Ko et al.
`11/1999 Ko et al.
`Ko et al.
`11/1999
`11/1999 Ding et al.
`11/1999 Ding et al.
`Ding et al.
`12/1999 Sherman
`12/1999 Sherman
`12/1999
`Sherman
`12/1999 Friedman et al.
`12/1999 Friedman et al.
`12/1999
`Friedman et al.
`12/1999 Hauer et al.
`12/1999 Hauer et al.
`12/1999
`Hauer et al.
`12/1999 Singh
`12/1999 Singh
`12/1999
`Singh
`12/1999 Al-Razzak et al.
`12/1999 Al-Razzak et al.
`12/1999
`Al-Razzak et al.
`2/2000 Klokkers et al.
`2/2000 Klokkers et al.
`Klokkers et al.
`2/2000
`2/2000 Hauer et al.
`2/2000 Hauer et al.
`Hauer et al.
`2/2000
`4/2000 Stuchlik et al.
`4/2000 Stuchlik et al.
`4/2000
`Stuchlik et al.
`5/2000 Mulye
`5/2000 Mulye
`5/2000
`Mulye
`12/2000 Sherman
`12/2000 Sherman
`12/2000
`Sherman
`3/2001 Sherman
`3/2001 Sherman
`3/2001
`Sherman
`7/2001 Garst
`7/2001 Garst
`7/2001
`Garst
`7/2001 Cho et al.
`7/2001 Cho et al.
`7/2001
`Cho et al.
`7/2001 Chen et al.
`7/2001 Chen et al.
`7/2001
`Chen et al.
`9/2001 Mishra et al.
`9/2001 Mishra et al.
`9/2001
`Mishra et al.
`9/2001 Patel et al.
`9/2001 Patel et al.
`9/2001
`Patel et al.
`10/2001 Cavanak
`10/2001 Cavanak
`10/2001
`Cavanak
`11/2001 Burke
`11/2001 Burke
`11/2001
`Burke
`2/2002 Singh et al.
`2/2002 Singh et al.
`Singh et al.
`2/2002
`2/2002 Garst
`2/2002 Garst
`2/2002
`Garst
`7/2002 Bennett et al.
`7/2002 Bennett et al.
`Bennett et al.
`7/2002
`7/2002 Richter et al.
`7/2002 Richter et al.
`Richter et al.
`7/2002
`10/2002 Cavanak et al.
`10/2002 Cavanak et al.
`10/2002
`Cavanak et al.
`11/2002 Meinzer et al.
`11/2002 Meinzer et al.
`11/2002
`Meinzer et al.
`11/2002 Olbrich et al.
`11/2002 Olbrich et al.
`11/2002
`Olbrich et al.
`4/2003 Tsuzuki et al.
`4/2003 Tsuzuki et al.
`4/2003
`Tsuzuki et al.
`4/2003 Matsuo
`4/2003 Matsuo
`4/2003
`Matsuo
`5/2003 Olejnik et al.
`5/2003 Olejnik et al.
`Olejnik et al.
`5/2003
`5/2003 Patel et al.
`5/2003 Patel et al.
`Patel et al.
`5/2003
`6/2003 Kawashima
`6/2003 Kawashima
`6/2003
`Kawashima
`12/2003 Benita et al.
`12/2003 Benita et al.
`Benita et al.
`12/2003
`3/2005 Lyons
`3/2005 Lyons
`3/2005
`Lyons
`1/2006 Bakhit et al. (cid:9)
`1/2006 Bakhit et al. (cid:9)
`I/2006
`Bakhit et al.
`4/2007 Chang
`4/2007 Chang
`4/2007
`Chang
`10/2007 Chang et al.
`10/2007 Chang et al.
`10/2007
`Chang et al.
`10/2007 Chang et al.
`10/2007 Chang et al.
`10/2007
`Chang et al.
`Chang
`11/2007
`Chang
`11/2007
`11/2007
`Chang
`Tien et al.
`3/2009
`Tien et al.
`3/2009
`3/2009
`Tien et al.
`Chang et al.
`7/2012
`Chang et al.
`7/2012
`7/2012
`Chang et al.
`Chang et al.
`10/2012
`Chang et al.
`10/2012
`10/2012
`Chang et al.
`Neuer et al.
`6/2001
`Neuer et al.
`6/2001
`6/2001
`Neuer et al.
`8/2001 Fischer et al.
`8/2001 Fischer et al.
`Fischer et al.
`g/2001
`11/2001 Garst
`11/2001 Garst
`11/2001
`Garst
`1/2002 Patel et al.
`1/2002 Patel et al.
`I/2002
`Patel et al.
`1/2002 Cavanak et al.
`1/2002 Cavanak et al.
`I/2002
`Cavanak et al.
`Floe'h et al.
`2/2002 Floc'h et al.
`2/2002 Floc'h et al.
`2/2002
`2/2002 Richter et al.
`2/2002 Richter et al.
`Richter et al.
`2/2002
`2/2002 Olbrich et al.
`2/2002 Olbrich et al.
`Olbrich et al.
`2/2002
`4/2002 Kawashima
`4/2002 Kawashima
`4/2002
`Kawashima
`8/2002 Petszulat et al.
`8/2002 Petszulat et al.
`Petszulat et al.
`g/2002
`8/2002 Meinzer et al.
`8/2002 Meinzer et al.
`Meinzer et al.
`g/2002
`11/2002 Richter et al.
`11/2002 Richter et al.
`11/2002
`Richter et al.
`1/2003 Kang et al.
`1/2003 Kang et al.
`I/2003
`Kang et al.
`3/2003 Ueno
`3/2003 Ueno
`3/2003
`Ueno
`3/2003
`Stergiopoulos et al.
`3/2003
`Stergiopoulos et al.
`3/2003
`et al.
`Stergiopoulos
`3/2003
`Muller
`3/2003
`Muller
`3/2003
`Muller
`3/2003
`Cavanak et al.
`3/2003
`Cavanak et al.
`3/2003
`Cavanak et al.
`5/2003 Or et al.
`5/2003 Or et al.
`Or et al.
`5/2003
`6/2003 Or et al.
`6/2003 Or et al.
`Or et al.
`6/2003
`6/2003 Benita et al.
`6/2003 Benita et al.
`Benita et al.
`6/2003
`6/2003 Or et al.
`6/2003 Or et al.
`Or et al.
`6/2003
`6/2003 Or et al.
`6/2003 Or et al.
`Or et al.
`6/2003
`7/2003 Ambuhl et al.
`7/2003 Ambuhl et al.
`et al.
`7/2003
`Ambuhl
`7/2003 Hauer et al.
`7/2003 Hauer et al.
`Hauer et al.
`7/2003
`8/2003 Yang et al.
`8/2003 Yang et al.
`Yang et al.
`g/2003
`9/2003 Fricker et al.
`9/2003 Fricker et al.
`Fricker et al.
`9/2003
`
`...........
`
`5,916,589
`5,916,589 A
`5,916,589 A
`5,929,030
`5,929,030 A
`5,929,030 A
`5,951,971
`5,951,971 A
`5,951,971 A
`5,962,014
`5,962,014 A
`5,962,014 A
`5,962,017
`5,962,017 A
`5,962,017 A
`5,962,019
`5,962,019 A
`5,962,019 A
`5,977,066 A
`5,977,066 A
`5,977,066
`5,981,479
`5,981,479 A
`5,981,479 A
`5,981,607
`5,981,607 A
`5,981,607 A
`5,998,365 A
`5,998,365 A
`5,998,365
`6,004,566 A
`6,004,566 A
`6,004,566
`6,007,840 A
`6,007,840 A
`6,007,840
`6,008,191 A
`6,008,191 A
`6,008, 191
`6,008,192 A
`6,008,192 A
`6,008, 192
`6,022,852 A
`6,022,852 A
`6,022, 852
`6,024,978
`6,024,978 A
`6,024,978 A
`6,046,163 A
`6,046,163 A
`6,046, 163
`6,057,289 A
`6,057,289 A
`6,057,289
`6, 159,933
`6,159,933 A
`6,159,933 A
`l
`6, 197,335
`6,197,335 Bl
`6,197,335 Bl
`Bl
`6,254,860 Bl
`6,254,860 Bl
`6,254, 860
`Bl
`6,254,885 Bl
`6,254,885 Bl
`6,254, 885
`Bl
`6,267,985 Bl
`6,267,985 Bl
`6,267,985
`Bl
`6,284,268 Bl
`6,284,268 Bl
`6,284,268
`Bl
`6,294,192 Bl
`6,294,192 Bl
`6,294, 192
`Bl
`6,306,825 Bl
`6,306,825 Bl
`6,306,825
`Bl
`6,323,204 Bl
`6,323,204 Bl
`6,323,204
`Bl
`6,346,511
`6,346,511 Bl
`6,346,511 Bl
`B2
`6,350,442 B2
`6,350,442 B2
`6,350,442
`Bl
`6,413,547
`6,413,547 Bl
`6,413,547 Bl
`B2
`6,420,355 B2
`6,420,355 B2
`6,420,355
`B2
`6,468,968
`6,468,968 B2
`6,468,968 B2
`Bl
`6,475,519
`6,475,519 Bl
`6,475,519 Bl
`B2
`6,486,124 B2
`6,486,124 B2
`6,486, 124
`B2
`6,544,953
`6,544,953 B2
`6,544,953 B2
`B2
`6,555,526 B2
`6,555,526 B2
`6,555,526
`B2
`6,562,873 B2
`6,562,873 B2
`6,562,873
`B2
`6,569,463 B2
`6,569,463 B2
`6,569,463
`6,582,718
`B2
`6,582,718 B2
`6,582,718 B2
`B2
`6,656,460 B2
`6,656,460 B2
`6,656,460
`B2
`6,872,705 B2
`6,872,705 B2
`6,872,705
`B2*
`6,984,628 B2 *
`6,984,628 B2 *
`6,984,628
`B2
`7,202,209 B2
`7,202,209 B2
`7,202,209
`B2
`7,276,476 B2
`7,276,476 B2
`7,276,476
`B2
`7,288,520 B2
`7,288,520 B2
`7,288,520
`B2
`7,297,679
`7,297,679 B2
`7,297,679 B2
`B2
`7,501,393
`7,501,393 B2
`7,501,393 B2
`8,211,855
`B2
`8,211,855 B2
`8,211,855 B2
`B2
`8,288,348 B2
`8,288,348 B2
`8,288,348
`Al
`2001/0003589 Al
`2001/0003589 Al
`2001/0003589
`Al
`2001/0014665 Al
`2001/0014665 Al
`2001/0014665
`Al
`2001/0036449 Al
`2001/0036449 Al
`2001/0036449
`Al
`2002/0012680 Al
`2002/0012680 Al
`2002/0012680
`Al
`2002/0013272 Al
`2002/0013272 Al
`2002/0013272
`Al
`2002/0016290 Al
`2002/0016290 Al
`2002/0016290
`Al
`2002/0016292 Al
`2002/0016292 Al
`2002/0016292
`Al
`2002/0025927 Al
`2002/0025927 Al
`2002/0025927
`Al
`2002/0045601 Al
`2002/0045601 Al
`2002/0045601
`Al
`2002/0107183 Al
`2002/0107183 Al
`2002/0107183
`2002/0119190
`Al
`2002/0119190 Al
`2002/0119190 Al
`Al
`2002/0165134 Al
`2002/0165134 Al
`2002/0165134
`Al
`2003/0021816 Al
`2003/0021816 Al
`2003/0021816
`Al
`2003/0044452 Al
`2003/0044452 Al
`2003/0044452
`Al
`2003/0055028 Al
`2003/0055028 Al
`2003/0055028
`Al
`2003/0059470 Al
`2003/0059470 Al
`2003/0059470
`A